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The driving force in the progression of COPD is the development of exacerbations which
are mostly the result of excessive inflammation. Bronchodilatators play an important role
in the treatment of COPD. The reported reduction in exacerbation rates in COPD is due to
the inhibition of vagal-mediated bronchoconstriction and mucus secretion. However,
recent studies have highlighted the existence of muscarinic receptors on inflammatory
cells and we have explored the possibility that tiotropium bromide might also inhibit
neutrophil migration. We analysed the influence of tiotropium on the release of neutrophil
chemotactic activity in response to acetylcholine (ACh) and the expression of muscarinic
receptors on human alveolar macrophages (AM), A549 cells, MonoMac6 cells, and human
lung fibroblasts. We found significant levels of all muscarinic receptor subtypes on all
analysed cells except the fibroblasts. Fibroblasts expressed predominantly M2, receptors
and did not release chemotactic activity. AM, A549 cells, and MonoMac6 cells released
chemotactic active mediators after incubation with ACh. The secretion could be
suppressed by more than 70% after coincubation with tiotropium. Tiotropium alone did
not influence the granulocyte migration. Most of the chemotactic activity could be
attributed to leukotriene B4 (LTB4). The release of interleukin-8 (IL-8) and monocyte
chemotactic protein-1 (MCP-1) was not induced by ACh. From this, we suggest that the
suppression of the Ach-mediated release of chemotactic substances like LTB4 modulatesPublished by Elsevier Ltd.
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Tiotropium suppresses chemokine release 2387the inflammatory reaction. This may contribute to the decreased rate of exacerbations in
COPD, which was observed in clinical trials.
& 2007 Published by Elsevier Ltd.Introduction
Chronic obstructive lung disease (COPD) is the only major
fatal disease which is increasing. At this time, COPD is the
fourth most common disease in the world. Therefore, this
disease will be one of the most important economical
factors in public health.1 The cause of COPD is attributed to
the burden of toxic gases and small particles that individuals
inhale during their lifetime. Although atmospheric pollution
contributes to this burden, the smoking of tobacco products
is the major risk factor.2 Recent findings indicate that lung
inflammation is present in all smokers. The reason why only
a minority of smokers develops significant air flow obstruc-
tion is still unknown, but preliminary evidence suggests that
the lung inflammatory response is amplified in this group.
The chronic inflammation induces remodelling of the
bronchial tissue and the up-regulation of protease activity
leading to emphysematous lung destruction. Furthermore,
an important factor in the course of COPD is the develop-
ment of exacerbations as a result of excessive inflammation
which is often caused by infectious agents. To date, there is
no causal therapeutic approach which targets the chronic
inflammatory processes.
Bronchodilatators play an important role in the treatment
of COPD and anti-cholinergics have a long history as an
effective and safe treatment.3 The use of ipratropium was
limited by the need for frequent dosing.4,5 Tiotropium, a
new anti-cholinergic agent exhibits a long duration of action
due to prolonged muscarinic receptor antagonism. The
compound dissociates from the M3-receptor subtype ex-
tremely slowly but rapidly from the M2 receptors.5
This offers the therapeutic advantage of once-daily dosing
combined with a kinetic selectivity towards the M3-
receptor subtype. Clinical trials with tiotropium have
shown its effectiveness as a bronchodilatator in COPD6
with marked influence on dyspnea reduction and improve-
ment of exercise tolerance.7 Additionally, tiotropium
reduces the exacerbation frequency in patients with COPD.6
These effects are associated with a beneficial effect on
the health status. The mechanisms that prevent the decline
in lung function and that are responsible for the reduction
in the exacerbation frequency after treatment with
tiotropium but not after treatment using drugs such
as ipatropium are unclear. It has been suggested that
tiotropium may have beneficial properties beside its
bronchodilatory efficiency resulting, e.g., in a decrease of
chronic inflammation in COPD patients.5 In general, the
selectivity of tiotropium for M3-muscarinic receptors is
higher compared to ipatropium and the duration of action is
longer. If M3-receptor antagonists suppress the release of
mediators that prevent inflammation or tissue remodelling,
tiotropium will assure a steady suppression of these
mediators.
Increased number of cells of the innate immune system is
one important characteristic of chronic inflammation inCOPD. These are mostly neutrophil granulocytes which
are attracted as a result of mediator release by activated
epithelial cells and resident cells of the monocyte/
macrophage lineage at the air/blood barrier of the alveoli
and the small conducting airways. The activation of these
cells at the site of inflammation may trigger airway
remodelling. In addition, it has been suggested that
chemokines, which attract neutrophils act directly on
fibroblasts and smooth muscle cells and thus promote airway
remodelling.8
Parasympathetic nerves provide the dominant autonomic
innervations of the airways. Release of acetylcholine
(ACh) from parasympathetic nerves activates muscarinic
receptors present on airway smooth muscles and submucosal
glands causing, e.g., bronchoconstriction and mucus
secretion which are important symptoms of COPD.9 In
addition to this signal transduction pathway of the para-
symphathetic nervous system, it has been shown that other
cell types, e.g., bovine bronchial epithelial cells and
alveolar macrophages (AM) are responsive to ACh stimula-
tion resulting in the release of chemotactic factors which
trigger granulocyte migration.8,10,11 This mechanism may
maintain the chronic inflammation in the airways in addition
to other physical and chemical triggers such as cigarette
smoke.
We postulated that tiotropium may regulate the release
of chemotactic factors from epithelial cells and macro-
phages because tiotropium was thought to have an
additional, anti-inflammatory function. This effect should
be mediated via muscarinic Ach-receptors on the cells
involved in the regulation of innate immune response in the
lung.Methods
Cell culture
Tissue samples from patients without lung fibrosis or COPD
were obtained from healthy tissue areas during pneumo-
nectomy for tumour resection from a tumour-free area. The
ethical committee of the University of Magdeburg approved
the study.
Fibroblasts were obtained by mincing freshly excised lung
parenchyma into 1mm3 pieces, followed by digestion with
collagenase IV (1mg/ml; Sigma, Deissenhofen, Germany) for
30min at 37 1C. Fibroblasts were cultured in a 75-ml tissue
culture flask containing Iscove’s modified Dulbecco’s med-
ium with 10% (w/v) foetal calf serum (FCS), 103 M
glutamine and antibiotics (growth medium, GM), at 37 1C
and 5% (v/v) CO2 until they reached confluence. Only
fibroblasts between passages 3 and 8 were used for the
experiments. The myelo-monocytic cell line MonoMac6 and
the bronchial epithelial cell line A549 were cultured in GM
and subdivided every 3 days.
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F. Bu¨hling et al.2388Bronchoalveolar lavage (BAL) and preparation of
alveolar macrophages (AM)
Only patients (non-smokers) without clinical signs of inter-
stitial, obstructive or infectious lung disease, who under-
went bronchoscopy for exclusion of lung tumour, were
included in this study. We included 10 patients (seven males,
three females, age between 48 and 71 years).
Bronchoscopy (Olympus model BF 20 D or the P 10
bronchoscope) was performed through the nasal orifice or
endotracheal tube. Topical anaesthesia (10ml 2% lidocaine)
was applied and the bronchoscope was advanced and
brought into wedge position in a segmental bronchus. If no
infiltration was evident on chest X-ray, bronchoalveolar
lavage (100ml of 0.9% saline solution at 37 1C sequentially
instilled and suctioned in 20-ml portions) was performed in
the right middle lobe.
BALF was filtered through sterile gauze filters, collected
on ice and immediately centrifuged at 200g for 10min. The
cell pellets were resuspended in cell culture medium and
counted. Differential cell counting was performed in May-
Gru¨nwald-Giemsa-stained cytocentrifuge preparations. Only
preparations witho3% granulocytes ando10% lymphocytes
were used for the experiments.RT-PCR
For quantitative RT-PCR, total RNA was isolated from cells
using RNeasy Mini kit (QIAGEN, Hilden, Germany). Remaining
DNA was digested using DNAse as described by the
manufacturer. The RNA was reverse transcribed by First
Strand DNA Synthesis kit (Amersham Pharmacia Biotech,
Freiburg, Germany). The PCR reaction was performed with
the help of primers described in Buchli et al.12 using the
Quantitect SYBR Green PCR Kit (QIAGEN) and a ABI7000 PCR
cycler (Applied Biosystems, Foster City, CA). The specificity
of PCR reactions was verified by melting curve analyses.
Additionally, the products were separated by agarose-gel
electrophoresis. The receptor mRNA expression was normal-
ised to b-actin mRNA compared between different cells
using the 2DDCT method.13Conditioned media
Fibroblasts (2 105 cells) and A549 cells (2 105 cells) were
seeded in 24-well plates and grown to confluence in RPMI
containing 10% foetal calf serum and antibiotics. MonoMac6
cells and AM were incubated at a concentration of 3.2 105
and 1 106 cells/ml, respectively. We used three indepen-
dent wells for each time period and each concentration of
ACh and tiotropium. For generation of conditioned medium,
the growth medium was replaced by Ham’s F12 medium. The
cells were incubated for different time periods (4–72 h) with
different concentrations of ACh (1–100 mM, Sigma, Deissen-
hofen, Germany) as indicated in the respective figures.
Tiotropium bromide (20 nM; Boehringer Ingelheim) was
added as indicated in the respective figures. The super-
natants were removed after the indicated time periods,
centrifuged to remove remaining cells and snap-frozen until
further use.The viability of the cells was measured after the removal
of the supernatants at the end of the incubation period using
propidium iodide and flow cytometry. The viability was
higher than 90% in all experiments.
Separation of granulocytes
Heparinised blood (10 IU/ml blood) from healthy donors was
used. PBMC were isolated by density gradient centrifugation
with Ficoll/Paque (Pharmacia) for 30min at 500 g.14
Supernatant, mononuclear cells and separation medium
were removed and the cell pellet containing the erythro-
cytes and the granulocytes was resuspended in equal volume
of polyvinylalcohol in 15-ml polypropylene tubes (BD,
Heidelberg, Germany). The suspension was incubated at
37 1C for 30min to allow the sedimentation of erythrocytes.
The granulocyte-rich supernatant was removed and remain-
ing erythrocytes were lysed using ice-cold 0.8% ammonium
chloride solution (3min). The purity of the isolated
granulocytes was determined by flow cytometry after
staining with anti-CD62L, anti-CD3, anti-CD19 and anti-
CD14 antibodies (BD Biosciences, Heidelberg, Germany).
Only cell population which contained more than 95% CD62L-
positive and CD3/CD19/CD14-negative cells were used for
the experiments. The cells were resuspended in ice-cold
RPMI at a concentration of 2 107 cells/ml.
Migration
Chemotaxis was assayed in a 24-well transwell chamber
(pore diameter 3 mm, BD). The bottom chamber was filled
one by one with conditioned medium, which has been
generated as described before. Isolated granulocytes
(100 ml, 2 106 cells) were placed in the upper chamber.
The transwells were incubated in a humidified atmosphere
with 5% CO2 for 30min at 37 1C. Non-migrated cells
were wiped away from the upper surface of the filter and
the filter was formalin fixed. The fixed cells were stained
using crystal violet solution (0.1% in 0.1M borate buffer with
2% ethanol) for 30min. Unbound stain was removed and the
bound crystal violet was extracted using 10% acidic acid
(10min, room temperature). The amount of bound stain as a
measure of the number of migrated cells was determined
photometrically at 570 nm. Spontaneous migration was
determined by adding GM alone. fMLP (1 106 M) was
added to the bottom chamber and used as positive control.
The values of the spontaneous migration were set to 100%
and used for the normalisation of different experiments.
The leukotriene B4 receptor was blocked by the selective
LTB4-receptor antagonist BIIL260 (100 nM; Boehringer Ingel-
heim) which was added to the upper compartment of the
migration chamber together with the isolated granulo-
cytes.15
Measurement of cytokine concentration
Commercially available ELISA kits were used (R&D Systems;
Minneapolis, MN, USA) for the detection of human inter-
leukin-8 (IL-8) and monocyte chemotactic protein-1 (MCP-1)
in culture supernatants.
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All statistical analyses were performed with SPSS 10.0 for
Windows (SPSS, Chicago, IL). Results were presented as mean
values7S.E. Mean values were compared by Student’s t-test.
In addition, the data were analysed using the non-parametric
Mann–Whitney U-test. Differences were considered to be
significant if the p-values were below 0.05 in both tests.
Results
Expression of muscarinic ACh receptors
First, we analysed the expression of muscarinic ACh
receptors on the isolated cells. The expression of M1, M2,
M3, M4, and M5-receptor mRNA was investigated by
quantitative RT-PCR in lung tissue homogenates, isolated
lung fibroblasts, A569 cells, and MonoMac6 cells. In the lung
tissue, A549 and MonoMac6 cells we found a nearly similar
pattern of expression of all five muscarinic ACh receptors
with a predominance of the M3 receptors. In contrast,
isolated lung fibroblasts expressed predominantly M2-re-
ceptor mRNA. The M2 receptor mRNA expression was
226-fold higher than the M3-receptor mRNA expression.
Fibroblasts expressed 35-times more M2-receptor mRNA
compared to A549 cells. The expression of the M3-receptor
mRNA was significantly lower in fibroblasts compared to
A549 cells (10% of the expression in A549 cells) and
MonoMac6 cells (Table 1). M5-receptor mRNA was expressed
at low amount and therefore not quantified. Compared to
the isolated cells, we found high ACh-receptor concentra-
tion in tissue homogenates that indicates the expression ofTable 1 Real-time RT-PCR quantification of muscarinic ACh re
Receptor Cells Fold-e
(compa
M1 A549 0.047
MonoMac6 0.147
Fibroblasts 0.087
Lung tissue 0.227
M2 A549 0.767
MonoMac-6 0.937
Fibroblasts 2267
Lung tissue 0.467
M3 A549 1
MonoMac-6 1
Fibroblasts 1
Lung tissue 1
M4 A549 0.847
MonoMac-6 0.847
Fibroblasts 0.487
Lung tissue 0.777
Quantitative RT-PCR was performed as described in section ‘‘Method
the expression of the M3 receptors in the respective cells (third colum
compared to the M3-receptor expression in A549 cells). The expressio
A549 cells (fourth column; for example, the expression of M3 recept
A549 cells. Values 41 mean increased expression. Values between 0muscarinic ACh receptors in cells such as neuronal cells or
airway smooth muscle cells.
ACh-induced release of chemotactic mediators
The release of chemotactic mediators was analysed with the
help of a two-step model described before by Sato et al.11;
Alveolar macrophages, MonoMac6 cells, A549 cells, and
isolated fibroblasts were incubated for different time periods
with increasing concentrations of ACh. The conditioned
supernatants were removed and tested for their chemotactic
activity on isolated granulocytes of healthy donors. First, we
defined the optimal time course and concentration of ACh in
different cells types. A dose-dependent release of chemotac-
tic activity was found in MonoMac6 cells and in A549 cells
after incubation with ACh at concentrations of 106–104M.
The release reached a maximum after 24h in MonoMac6 cells
and after 48h in A549 cells (Fig. 1A and B). Due to the limited
cell number in the BALF of single patients, only a concentra-
tion of 104M ACh has been used for stimulation of AM. We
found a more rapid response. The release was increased after
4h and reached a significant level after 8 h (Fig. 1C).
Fibroblasts did not release chemotactic substances (data not
shown). From this, it can also be concluded that ACh in the
conditioned medium did not induce migration of granulocytes.
Suppression of ACh action by tiotropium
Based on these findings, we hypothesised that the long-
acting antimuscarinic tiotropium may block the pro-inflam-
matory action of ACh. Therefore, the cells were incubated
with ACh in the presence and absence of tiotropium (20 nM).ceptors.
xpression
red to M3-receptors)
Fold-expression
(compared to A549)
0.02 1
0.02 110759
0.04 2.672.5
0.03 44677751
0.02 1
0.07 1776
16 3574
0.24 264718
1
49719
0.170.03
903728
0.02 1
0.05 1575
0.16 0.0470.02
0.13 9027142
s’’. The expression of different ACh-receptors was compared to
n; for example, the expression of M1 receptors in A549 cells was
n of distinct receptors was compared between different cells and
or in fibroblasts was compared to the M3 receptor expression in
and 1 mean decreased expression.
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Figure 1 Release of chemotactic activity after incubation with acetylcholine (ACh). MonoMac6 cells (A), A549 cells (B), and AM
(C) were incubated with ACh at concentrations of 1 mmol/l (circle), 10mmol/l (diamond), 100 mmol/l (triangle) or without ACh
(square). The chemotactic activity was assayed as described in section ‘‘Methods’’. In control experiments, granulocytes were
incubated with fMLP. The spontaneous migration of granulocytes which were incubated with native culture medium was set to 100%.
The results of five experiments are presented as mean7SEM. Asterisks indicate significant (po0.05) differences between the
chemotactic activity of unstimulated and ACh-stimulated cells at the given time point.
F. Bu¨hling et al.2390Previous experiments investigating the effect on human
bronchi have shown that this concentration effectively
inhibited constrictions induced by electric field stimula-
tions.16 Fig. 2 shows that tiotropium significantly inhibited
the release of chemotactic substances by AM, MonoMac6 and
A549 cells. Tiotropium alone did not change the chemotactic
activity, arguing for a direct competition with ACh for
binding to the muscarinic receptors. Furthermore, we have
demonstrated that preincubation with tiotropium did not
increase the observed effect (not shown). Release of
chemotactic mediators was not detected in fibroblasts
incubated with ACh.
Considering the different receptor expression in fibro-
blasts compared to all other cell types which were included
in our study, the absence of the pro-inflammatory action of
ACh and, consequently, the inhibition by tiotropium on
fibroblasts may be contributed to the low M3-receptor
expression in comparison to the M2 receptor. Overall, the
results demonstrate one mechanism of a possible anti-
inflammatory role of tiotropium.
Influence of ACh on chemokine release
No effect of cholinergic stimulation on the concentration of
IL-8 or MCP-1 was found (data not shown).Sato and co-workers10,11,17 have shown that the eicosa-
noid leukotriene B4 (LTB4) is released by bovine bronchial
epithelial in response to Ach. Consequently, we used the
specific LTB4-receptor antagonist BIIL260 to test whether
LTB4 mediated the ACh-induced chemotactic activity. Addi-
tion of the LTB4 inhibitor caused an inhibition of the
migration of the granulocytes in response to the conditioned
supernatants from AM, MonoMac6 cells, and A549 cells
(Fig. 3). Interestingly, BIIL260 inhibited both the ACh-
induced migration and the unspecific migration induced
by the supernatants of cells incubated without ACh.
We suggest that the unspecific migration was the result of
the spontaneous release of growth factors by the cultured
cells.Discussion
The development of COPD is associated with chronic
inflammation of the central airways, obstruction of small
airways and emphysematous destruction of the lung’s elastic
recoil force.2 Inflammatory cells from both the innate and
the adaptive immune response participate in this process.18
The accumulation of these cells seems to be mediated by
limitations in the capillary blood flow and, in addition, by
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Figure 2 Inhibition of chemotactic activity by tiotropium. MonoMac6 cells (A), A549 cells (B), and AM (C) were stimulated without
(0) or with ACh (100 mmol/l) and tiotropium (TIO, 20 nM) for 24, 48, or 8 h. The conditioned supernatants were used to stimulate
granulocyte migration. Tiotropium alone did not significantly influence the migration of human neutrophilic granulocytes. In control
experiments, granulocytes were incubated with fMLP. The spontaneous migration of granulocytes which were incubated with native
culture medium was set to 100%. The results of four experiments are presented as mean7SEM. Asterisks indicate significant
(po0.05) differences between the indicated samples.
Tiotropium suppresses chemokine release 2391chemotactic factors which are released by activated
macrophages, epithelial cells and fibroblasts.
As COPD progresses, the increased frequency and severity
of exacerbations become notable. Increased exacerbation
frequency has been associated with worsening the quality of
life and is predictive of an earlier mortality.6 One of the
most important health outcomes of the studies evaluating
tiotropium in COPD was the alteration in exacerbation
frequency as well as prolonging the time to the first
exacerbation.4,6 Therefore, it was suggested that tiotropium
has the potential to affect broader issues beyond sympto-
matic improvement. The mechanism of these effects
remained unclear.
Focussing on the extraneuronal actions of Ach,15 which
were described before, we have shown that tiotropium
decreases the release of chemotactic mediators from
epithelial cells and macrophages. This may suppress the
inflammatory reaction in the lung and thus contribute to
the prevention of exacerbations. Furthermore, the study
of Gosens et al. has shown that tiotropium prevented
the allergen-induced remodelling of airway smooth muscle
in vivo.19In detail, we have shown that various lung cells express
different patterns of muscarinic ACh receptors which may
point to a variable action of ACh on different lung cells. The
presence of muscarinic ACh receptors especially of the
M2-type has been demonstrated before on human lung
fibroblasts.20,21 We have found that fibroblasts expressed
predominantly M2-receptor mRNA and only lower amount of
M3-receptor mRNA. Similar findings have been published
recently by Matthiesen et al.22 A549 cells and MonoMac6
cells expressed more M3-receptor mRNA which could explain
the different responsiveness to ACh of A549 and MonoMac6
cells compared to fibroblasts.
Non-neuronal functions of ACh have been discussed
before by different authors.11,23 Salari and Chan-Yeung have
shown that ACh potentates the release of the pro-
inflammatory 15-HETE and of PGE2 at concentrations of
107–104 M.24 Sato et al.9 have described that ACh induces
the release of chemotactic agents by bovine AM. Using
specific inhibitors they determined that muscarinic M3
receptors and not nicotinic or muscarinic M1 or M2 receptors
were involved in this process. In contrast to these results it
has been described by Tracey and co-workers that ACh
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Figure 3 Inhibition of chemotactic activity by the selective leukotriene B4 receptor antagonist BIIL260. MonoMac6 cells (A), A549
cells (B), and AM (C) were stimulated with ACh (100 mm/l) for 24, 48, or 8 h. Neutrophil chemotactic activity was analysed in the
presence and absence of BIIL260. In control experiments, granulocytes were incubated with BIIL260 or fMLP. The spontaneous
migration of granulocytes which were incubated with native culture medium was set to 100%. The results of four experiments are
presented as mean7SEM. Asterisks indicate significant (po0.05) differences between the indicated samples.
F. Bu¨hling et al.2392initiates the ‘‘systemic anti-inflammatory pathway’’.25–27
They have shown that central muscarinic M1 and M2
receptors and the nicotinic ACh-receptor alpha7 subunit
are involved in the regulation of this pathway. One
explanation of these contrasting results could be the
predominant action of different receptors in defined cell
types.
We have shown that ACh at concentrations between 106
and 104 M induced a significant release of chemotactic
substances from human AM and from a human myeloid and a
lung epithelial cell line. Klapproth et al.28 have found
significant amounts of ACh (33 pmol/g) at bronchial epithe-
lial surface. Wessler et al.29 have shown that freshly
dissected tracheal tissue contains considerable amount of
Ach. Electrical stimulation increased the ACh release. The
concentration of ACh at the neuromuscular junction was
reported to be 104–103 M.30 There are no reported data
concerning the release of ACh in inflamed tissues or after
cytokine stimulation. Therefore, we suggest that the
concentrations used in our experiments are within the
patho-physiological range of human lung tissue. We cannot
exclude that there is an additional suppressive action of
nicotinic ACh receptors on the chemokine release becausewe have not used an antagonist of these receptors and have
not investigated their expression on our cells.
The time course of the release of chemotactic activity
varied between the different cells types. We found
increased chemotactic activity in the supernatant of
macrophages after 6–8 h and in A549 cells and MonoMac6
cells after 24–48 h. Interestingly enough, recent studies
found very similar differences between macrophages,
monocytes, and epithelial cells.10,11,17 The subcellular
mechanisms which regulate the kinetic of the synthesis of
chemotactic cytokines and especially of leukotrienes are not
fully identified. It has been shown that the efficiency and
the capacity of the leukotriene synthesis depend largely on
the membrane organisation of the components of the
synthetic machinery which is different in different cell
types.30,31 This could be one explanation for the variations
in the time course of the release of chemotactic activity.
Different cytokines such as IL-8 and LTB4 have been shown
to be increased in the sputum and the exhaled breath
condensate of COPD patients.32,33 Beeh et al.23 have
published that anti-IL-8 antibodies and the LTB4 antagonist,
SB201146, inhibited neutrophil chemotaxis which was
evoked by sputum from patients with COPD. We have
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Tiotropium suppresses chemokine release 2393investigated whether ACh enhances the release of IL-8 and
MCP-1 because we have shown before that they are released
from epithelial and myeloid cells.34 ACh did not induce the
secretion of these chemokines. This is in accordance with
data published by Sato et al.9 They have shown that anti-IL-8
antibodies did not suppress the chemotactic acivity induced
by human AM in response to ACh. However, using the specific
LTB4 inhibitor BIIL260, we could suppress both the complete
ACh-induced chemotactic activity and part of the unstimu-
lated chemotactic activity induced by the cells incubated
without ACh. From this, we conclude that LTB4 is an
important chemotactic mediator, released upon unspecific
stimuli and, in higher concentrations, after M3-receptor-
dependent stimulation, by ACh. We suggest, therefore, that
the LTB4 release is suppressed by tiotropium. This may
contribute to its potential anti-inflammatory action. Against
a cytotoxic or unspecific action of the antagonist on
granulocytes argues the fact that there was no inhibition
of the spontaneous migration of granulocytes. Interestingly,
these data would also suggest that LTB4 inhibitors should
influence the course of COPD. This hypothesis should be
further investigated in clinical studies.
In conclusion, we have shown for the first time that
tiotropium suppresses the ACh-induced release of chemo-
tactic agents from primary human macrophages as well as
from myeloid cell and epithelial cell lines via the blockade
of muscarinic receptors. The chemotactic activity was
mainly mediated by leukotriene B4. This mechanism may
possibly explain an anti-inflammatory action of tiotropium
which may contribute to a reduced exacerbation frequency
observed in clinical studies. Further studies confirming these
findings in vivo are necessary.
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